These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9096191

  • 1. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
    Shonekan D, Handwerger S, Mildvan D.
    J Antimicrob Chemother; 1997 Mar; 39(3):405-9. PubMed ID: 9096191
    [Abstract] [Full Text] [Related]

  • 2. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.
    Freeman C, Robinson A, Cooper B, Mazens-Sullivan M, Quintiliani R, Nightingale C.
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):47-50. PubMed ID: 7789096
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 4. Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.
    Johnson DM, Jones RN.
    Diagn Microbiol Infect Dis; 1996 Jan; 24(1):53-7. PubMed ID: 8988765
    [Abstract] [Full Text] [Related]

  • 5. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Cohen MA, Huband MD.
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):43-6. PubMed ID: 9990475
    [Abstract] [Full Text] [Related]

  • 6. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, Schmitz FJ.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [Abstract] [Full Text] [Related]

  • 7. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
    Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW.
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
    Qadri SM, Ueno Y, Abu Mostafa FM, Halim M.
    Chemotherapy; 1997 Dec; 43(2):94-9. PubMed ID: 9084917
    [Abstract] [Full Text] [Related]

  • 9. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
    von Eiff C, Peters G.
    J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
    [Abstract] [Full Text] [Related]

  • 10. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
    Sefton AM, Maskell JP, Rafay AM, Whiley A, Williams JD.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
    [Abstract] [Full Text] [Related]

  • 11. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ.
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
    Hershberger E, Aeschlimann JR, Moldovan T, Rybak MJ.
    Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.
    Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC.
    Antimicrob Agents Chemother; 1993 Mar; 37(3):598-601. PubMed ID: 8460927
    [Abstract] [Full Text] [Related]

  • 14. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C, Valverde JF, Culebras E, Gómez M, Sánchez A, Palau ML, Picazo JJ.
    Enferm Infecc Microbiol Clin; 1999 Mar; 17(7):335-9. PubMed ID: 10535185
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
    Dowzicky M, Nadler HL, Feger C, Talbot G, Bompart F, Pease M.
    Am J Med; 1998 May 29; 104(5A):34S-42S. PubMed ID: 9684656
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
    Giamarellos-Bourboulis EJ, Sambatakou H, Grecka P, Giamarellou H.
    Eur J Clin Microbiol Infect Dis; 1998 Sep 29; 17(9):657-61. PubMed ID: 9832270
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP, Mouton JW, den Hollander JG, van den Braak N, Verbrugh HA.
    Antimicrob Agents Chemother; 1997 May 29; 41(5):1146-9. PubMed ID: 9145886
    [Abstract] [Full Text] [Related]

  • 18. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE.
    Chemotherapy; 1998 May 29; 44(2):85-93. PubMed ID: 9551237
    [Abstract] [Full Text] [Related]

  • 19. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS, Nathan C, Hariharan R, Kostman JR, Kabins SA, Weinstein RA.
    Chemotherapy; 1996 May 29; 42(4):235-9. PubMed ID: 8804789
    [Abstract] [Full Text] [Related]

  • 20. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb 29; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.